Toggle navigation
Home
Feed
Channels
Profile
Home
Feed
Channels
Profile
Medspoke's Talks
Medspoke
Medspoke
Gastric Cancer
Published October 21, 2026
Beyond 30-day mortality: causes and risk factors of half-year postdischarge mortality after gastr...
October 23, 2026
Medspoke
Medspoke
Gastroenterology
Published October 21, 2026
00:00
--:--
Mevalonate Biosynthesis is a Metabolic Vulnerability of Gemcitabine-resistant Pancreatic Cancer.
October 23, 2026
Share
Mevalonate Biosynthesis is a Metabolic Vulnerability of Gemcitabine-resistant Pancreatic Cancer.
https://www.medspoke.co/channel_journal?id=785&tap_id=16099
Copy Link
Email
X
Bluesky
WhatsApp
LinkedIn
Facebook
Reddit
Medspoke
Medspoke
Clinical Colorectal Cancer
Published October 2, 2026
Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab as Third-Lin...
October 23, 2026
Why are you reporting this TALK?
